Zenex Animal Health India Private Ltd, backed by Multiples PE has announced the acquisition of a majority stake in Netherlands-based VievePharm, a specialist in natural animal nutrition, for an undisclosed amount. 

This would accelerate Zenex’s expansion into the global “naturals” market while establishing a dedicated manufacturing and sales hub in Western Europe, the company said. 

This acquisition allows Zenex to utilise VievePharm’s established distribution network in the EU to accelerate the export of its broader therapeutic and nutritional range across multiple formulation types. 

Dr. Arun Atrey, Managing Director and CEO of Zenex Animal Health, said, “The acquisition of VievePharm is a logical progression of our first-principles approach to animal healthcare — focusing on prevention and sustainable productivity.”

“By combining VievePharm’s advanced bolus technology and European market access with our R&D depth and global distribution, we are positioned to offer holistic, science-backed solutions that address the root causes of animal health challenges,” he added. 

Manish Gaur, Board member, Zenex, and MD & Head of Pharma and Healthcare at Multiples, said, “Strategic acquisitions that provide important capability additions, like VievePharm’s bolus technology and European footprint, will continue to be a vital part of the value-creation journey at Zenex as we scale our leadership globally.”

Arie Boorsma, Founder, VievePharm, said, “Joining forces with Zenex allows us to scale our ‘Best of Nature’ philosophy to a global stage. Our commitment to sustainable livestock farming and innovation in animal nutrition aligns perfectly with Zenex’s vision. This partnership will provide the resources and reach necessary to deepen our operations in The Netherlands and take our solutions to farmers across Europe and RoW markets.”